Potencial prognóstico da expressão de COX-2 e VEGF-C no adenocarcinoma colorretal de pacientes de um Hospital de referência do SUS no tratamento oncológico
Carregando...
Data
2012-03-23
Autores
Título da Revista
ISSN da Revista
Título de Volume
Editor
Universidade Federal de Goiás
Resumo
BACKGROUND: Colorectal adenocarcinoma (CRA) is a worldwide
distributed pathology, and lymph node metastasis is associated with a poor
prognostic outcome. Angiogenesis and lymphangiogenesis are correlated
with metastasis. Vascular endothelial growth factor C (VEGF-C) and
Cyclooxygenase 2 (COX-2) are molecules directly involved in those
processes. We investigated the possible association of the expression of
VEGF-C and COX-2 with clinical/pathology features and five year survival
rate.
MATERIALS AND METHODS: One hundred and thirty four cases of
CRA from a Cancer Reference Hospital were randomly selected. The
expression of VEGF-C and COX-2 was detected by immunohistochemistry
and a univariate analysis was applied to evaluate the association between
their expression and clinical stages, metastasis, and/or survival.
RESULTS: COX-2 expression was observed in 98.67% of the
adenocarcinoma cases while VEGF-C was found in 54.48% of the cases.
COX-2 was highly expressed by all clinical stages of CRA, but its
expression was not associated with LN metastasis, tumor infiltration or five
years survival. A correlation was observed between LN metastasis and
VEGF-C positivity (p=0.02) and clinical stages of the disease. The range of
VEGF-C expressions was from 34.6% to 88.9% in stages 1 through 4,
respectively.
CONCLUSION: The majority of the CRA cases were positive for COX-2.
It was observed association between the expression of VEGF-C and LN
metastasis as well as with clinical stages of the disease, although no
association was found to the overall five year survival rate.
Descrição
Palavras-chave
colorretal , câncer , VEGF-C , COX-2 , tumor , colorectal , cancer , VEGF-C , COX-2 , adenocarcinoma , tumor
Citação
MOTA, Eliane Duarte. Role of VEGF-C; COX-2; Colorectal; adenocarcinoma. 2012. 106 f. Dissertação (Mestrado em Medicina) - Universidade Federal de Goiás, Goiânia, 2012.